The transaction, expected to close by the end of 2021, is the largest in PerkinElmer’s history.
Under the deal, BioLegend’s San Diego campus will become PerkinElmer’s global center of excellence for research reagent content development.
BioLegend has estimated 2022 revenue of $380 million.
Read the full news release here.
